肝门部胆管癌门静脉切除重建的技术要点:名古屋大学医院经验
本文系统综述大容量中心门静脉切除重建(PVR)的现有证据与外科实践,旨在界定PVR安全实施时机与方法。基于现有证据,建议仅在肿瘤与拟保留侧肝脏流入道血管存在真正黏附侵犯时实施PVR,不推荐常规非接触性血管切除重建。名古屋大学医院大宗病例中,血管切除重建组90天病死率高于非重建组(3.6%比1.2%),但两组中位总体生存期均达30个月,远高于非手术组(10个月)。
要点
- 仅当肿瘤与拟保留侧肝脏流入道血管存在真正黏附侵犯时实施PVR。
- 不推荐常规行非接触性血管切除重建。
- 血管切除重建组90天病死率高于非重建组,但两组中位生存期均达30个月。
核心结论
- 进展期肝门部胆管癌联合门静脉切除重建的肝切除术常是唯一可行手术方案,但需严格掌握PVR指征。
研究设计与样本
- 本文为系统综述,阐述大容量中心PVR的现有证据与外科实践,总结PVR手术疗效。
- 名古屋大学医院大宗肝门部胆管癌病例中,比较血管切除重建组与非重建组的90天病死率及生存期。
主要发现
- 手术切除患者中血管切除重建组90天病死率高于非重建组(3.6%比1.2%)。
- 血管切除重建组与非重建组的中位总体生存期均达到30个月。
- 非手术组中位总体生存期为10个月,远低于手术切除两组。
关键数值与推荐
- 建议仅在肿瘤与拟保留侧肝脏的流入道血管存在真正黏附侵犯时实施PVR。
- 不推荐常规行非接触性血管切除重建。
临床怎么用
- 术前评估应明确肿瘤与拟保留侧肝脏流入道血管是否存在真正黏附侵犯,以决定是否行PVR。
- PVR实施需参照大容量中心标准流程,关注吻合失败征象、自体间置移植物选择及术后门静脉血栓抗凝治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Perihilar cholangiocarcinoma (PHCC) frequently invades the portal venous system. For advanced PHCC (e.g., cT4 stage), hepatectomy combined with portal vein resection and reconstruction (PVR) is often the only feasible surgical option. However, the complexity of PVR techniques and the concurrent need for extensive hepatectomy significantly increase perioperative mortality risks. This article systematically reviews the current evidence and surgical practices of high-volume center PVR, aiming to define the optimal timing and methods for safe PVR implementation, and summarizes the surgical outcomes of PVR, including the incidence of portal vein thrombosis complications and long-term survival rates. Based on existing evidence, PVR is recommended only when there is genuine adhesion invasion between the tumor and the inflow vessels of the future liver remnant, and routine no-touch vascular resection and reconstruction (VR) is not recommended. In a large cohort of PHCC cases at Nagoya University Hospital, the 90-day mortality rate in the VR group was higher than that in the non-VR group (3.6% vs. 1.2%), but both groups achieved a median overall survival of 30 months, significantly higher than the non-surgical group (10 months). Additionally, the article details the standard PVR protocol at Nagoya University Hospital, signs of anastomotic failure, selection of autologous interposition grafts, postoperative surveillance, and anticoagulation therapy for portal vein thrombosis. 肝门部胆管癌(PHCC)常侵犯门静脉系统,针对进展期PHCC(如cT4期),联合门静脉切除重建(PVR)的肝切除术常是其唯一可行的手术方案。然而,PVR技术的复杂性及同期需行大范围肝切除,显著增加了围手术期死亡风险。本文系统阐述了大容量中心PVR的现有证据与外科实践,旨在界定PVR的安全实施时机与方法,并总结了PVR的手术疗效,包括门静脉血栓并发症发生率及长期生存率。基于现有证据,建议仅在肿瘤与拟保留侧肝脏的流入道血管存在真正黏附侵犯时实施PVR,不推荐常规行非接触性血管切除重建(VR)。在名古屋大学医学部附属病院大宗PHCC病例中,手术切除患者中VR组的90 d病死率高于非VR组(3.6%比1.2%),但两组的中位总体生存期均达到30个月,远高于非手术组(10个月)。同时,本文介绍了名古屋大学医学部附属病院PVR的标准流程、吻合失败的征象、自体间置移植物的选择及术后的监测事项、门静脉血栓形成的抗凝治疗方法等。.
引用
- Tomoki TZX, Takashi YLS, Shunsuke SSJ, et al. [Technical points of portal vein resection and reconstruction for perihilar cholangiocarcinoma: based on the experience of Nagoya University Hospital]. Zhonghua Wai Ke Za Zhi. 2026. PMID: 41771517. doi:10.3760/cma.j.cn112139-20251127-00550
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。